8-K current report · filed Jul 7, 2026

MeiraGTx Holdings plc (MGTX) 8-K Current Report: July 7, 2026

Item 1.01Item 1.02Item EX-99.1Item 2.03Item 3.02Item 7.01MGTX overview

Short answer

MeiraGTx Holdings plc (MGTX) filed an 8-K current report with the SEC on July 7, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure). Up to $375M in senior secured royalty financing, with $100M initial and $25M second purchases.

MeiraGTx Holdings plc 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Up to $375M in senior secured royalty financing, with $100M initial and $25M second purchases
  • Future $50M tranches tied to AQUAx2 data, bota-vec approval, and AAV-hAQP1 approval
  • Investors receive 1.95% of global net sales from AAV-AIPL1, AAV-hAQP1, and bota-vec after approvals
  • Financing secured by cash, equity, receivables, property, and product-related assets, increasing creditor priority
  • Separate $10M equity placement of 950,570 shares at $10.52, plus investor option for up to $15M additional shares
  • Resale registration required by November 15, 2026, creating potential future share supply and dilution overhang

Item 1.02 · Termination of a Material Definitive Agreement

  • Perceptive NPA fully terminated following repayment of all outstanding principal on June 30, 2026
  • Accrued unpaid interest and redemption-related fees paid alongside principal
  • No early termination penalties incurred, limiting exit costs
  • Remaining obligations limited to contingent indemnification and reimbursement provisions

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 links to Item 1.01 for the material agreement creating MeiraGTx’s direct financial obligation
  • Investor impact depends on Item 1.01 terms, including obligation amount, interest rate, maturity and funding purpose

Item 3.02 · Unregistered Sales of Equity Securities

  • Item 3.02 links to Item 1.01, indicating an unregistered equity issuance connected to a material agreement
  • Investor impact depends on Item 1.01 terms, including securities issued, consideration received and potential dilution

Item 7.01 · Regulation FD Disclosure

  • July 7, 2026 press release announces entry into a Royalty Note Purchase Agreement
  • Agreement creates future obligations tied to royalty-note financing
  • Completion remains subject to offering terms, market conditions and customary closing conditions
  • Investors should review Exhibit 99.1 for transaction economics and potential dilution or royalty burden

Item EX-99.1 · Exhibit EX-99.1

  • Up to $400M strategic financing, including $375M non-dilutive royalty funding and $25M equity
  • Initial $135M funded: $125M royalty financing plus $10M equity investment
  • Additional $150M tied to 2027–2028 clinical and regulatory milestones for AAV2-hAQP1 and bota-vec
  • Oberland receives capped low-single-digit royalties on three potential gene therapies after approval
  • Financing supports commercialization while limiting dilution, but future product sales carry royalty obligations

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MeiraGTx Holdings plc 8-K filings

Get the next MGTX 8-K as it lands

Follow MGTX for push alerts, or ask the research agent what this filing means.